Immunology and Biotherapies
20.4K views | +1 today
Follow
 
Scooped by Gilbert C FAURE
onto Immunology and Biotherapies
Scoop.it!

Miraculous transplantation of a leg » Retronaut

Miraculous transplantation of a leg » Retronaut | Immunology and Biotherapies | Scoop.it
Miraculous transplantation of a leg - A verger's dream: Saints Cosmas and Damian performing a miraculous cure by transplantation of a leg.
more...
No comment yet.
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert C FAURE's insight:

We choose Scoop.it as preferred curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

The right angle on IL-2 therapy

The right angle on IL-2 therapy | Immunology and Biotherapies | Scoop.it
Engineered cytokines are able to improve immunotherapy in mouse tumor models.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

TGF-β Inhibition and Immunotherapy: Checkmate

TGF-β Inhibition and Immunotherapy: Checkmate | Immunology and Biotherapies | Scoop.it
Immune checkpoint therapy can induce durable remissions, but many tumors demonstrate
resistance. In a recent issue of Nature, Mariathasan et al. (2018) and Tauriello et al.
(2018) identify stromal TGF-β signaling as a determinant of immune exclusion. Combination
TGF-β inhibition and immunotherapy induces complete responses in mouse models.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

CAR Lentiviral Packaging Service - Creative Biogene

CAR Lentiviral Packaging Service - Creative Biogene | Immunology and Biotherapies | Scoop.it
Creative Biogene has developed CAR lentiviral packaging service based on most advanced techniques and extensive experience.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Inhibiting EBV: The Key to Carefree Smooching

Inhibiting EBV: The Key to Carefree Smooching | Immunology and Biotherapies | Scoop.it
There are no vaccines or therapies to treat Epstein-Barr virus (EBV). Snijder et al.
(2018) isolated a potent human antibody against EBV that blocks infection of both
B cells and epithelial cells. Structural analysis of the antibody complexed with a
viral surface protein complex identified a site that may be useful in vaccine development.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Introducing a New Series: Immunotherapy Facts and Hopes

Introducing a New Series: Immunotherapy Facts and Hopes | Immunology and Biotherapies | Scoop.it
The field of cancer immunotherapy is no longer in its infancy. Two lines of progress in clinical research are achieving true clinical success: (i) checkpoint blockade for solid tumors and (ii) chimeric antigen receptor (CAR) T-cell therapy for lymphoid malignancies ([1][1]). Clinical Cancer Research
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Hello RNA

Hello RNA | Immunology and Biotherapies | Scoop.it
BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high level of interest in finding new ways to manipulate immune cells.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

A nanoscale reorganization of the IL-15 receptor is triggered by NKG2D in a ligand-dependent manner

A nanoscale reorganization of the IL-15 receptor is triggered by NKG2D in a ligand-dependent manner | Immunology and Biotherapies | Scoop.it
Natural killer (NK) cells perform immune surveillance for virally infected cells and tumor cells. The balance between the engagement of activating receptors, such as NKG2D, and inhibitory receptors on the NK cell surface determines whether the cells kill their targets. Through superresolution microscopy, Bálint et al . showed that NKG2D on the surface of unstimulated NK cells was organized into nanoclusters, which became differentially reorganized depending on whether the cells were exposed to MICA or ULBP2, two NKG2D ligands found on tumor cells. Stimulation with ULBP2, but not MICA, caused NKG2D to cluster with the receptor for the cytokine IL-15, which can also be presented on tumor cells, synergizing with NKG2D to enhance NK cell responses. These data suggest that NKG2D ligands have distinct outcomes on NK cell function, which may have relevance in the use of NK cells as an immunotherapy.
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Cell Selections 2018: The CAR T Cell Revolution

Cell Selections 2018: The CAR T Cell Revolution | Immunology and Biotherapies | Scoop.it
Cell Press, working in conjunction with the Molecular Therapy family of journals, has created an editorially curated collection of articles that highlights the current state of the art in the development of CAR T cell therapies.

Via Krishan Maggon
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

The Pharmacology of T Cell Therapies

The Pharmacology of T Cell Therapies | Immunology and Biotherapies | Scoop.it
Adoptive cellular therapy using T cells with tumor specificity derived from either
natural T cell receptors (TCRs) or an artificial chimeric antigen receptor (CAR) has
reached late phase clinical testing, with two CAR T cell therapies achieving regulatory
approval within the United States in 2017. The effective use of these therapies depends
upon an understanding of their pharmacology, which is quite divergent from traditional
small molecule or biologic drugs. We review the different types of T cell therapy
under clinical development, the factors affecting cellular kinetics following infusion,
and the relationship between these cellular kinetics and anti-cancer activity.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

“Idling” cancer cells may return | Vanderbilt News

“Idling” cancer cells may return | Vanderbilt News | Immunology and Biotherapies | Scoop.it
Vanderbilt investigators have discovered that cancer treatment induces an “idling” state for cells, which could promote resistance to treatment.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Role of Anti-MICA Antibodies in Graft Survival of Renal Transplant Recipients of India

Role of Anti-MICA Antibodies in Graft Survival of Renal Transplant Recipients of India | Immunology and Biotherapies | Scoop.it
Journal of Immunology Research is a peer-reviewed, Open Access journal that provides a platform for scientists and clinicians working in different areas of immunology and therapy. The journal publishes research articles, review articles, as well as clinical studies related to classical immunology, molecular immunology, clinical immunology, cancer immunology, transplantation immunology, immune pathology, immunodeficiency, autoimmune diseases, immune disorders, and immunotherapy.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Boosting Immunotherapy Treatments in Mouse Colon Cancer | The Scientist Magazine®

Boosting Immunotherapy Treatments in Mouse Colon Cancer | The Scientist Magazine® | Immunology and Biotherapies | Scoop.it
Mice treated with an immunostimulant had better outcomes when researchers blocked the expression of TNFR2, a compound that helps tumors evade immune attack.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Dermatologic manifestations of solid organ transplantation-associated graft-versus-host disease: A systematic review. - PubMed - NCBI

Dermatologic manifestations of solid organ transplantation-associated graft-versus-host disease: A systematic review. - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
Format: AbstractSend to J Am Acad Dermatol. 2017 Dec 26. pii: S0190-9622(17)32890-6. doi: 10.1016/j.jaad.2017.12.050. [Epub ahead of print] Dermatologic manifestations of solid organ transplantation-associated graft-versus-host disease: A systematic review. Kim GY1, Schmelkin LA2, Davis MDP3, El-Azhary RA3, Farrell AM4, Meves A3, Lehman JS5. Author information 1 Mayo Clinic School of Medicine, Rochester, MN, USA. 2 Mayo Clinic School of Graduate Medical Education, Mayo Clinic, Rochester, MN, USA. 3 Department of Dermatology, Mayo Clinic, Rochester, MN, USA. 4 Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, USA. 5 Department of Dermatology, Mayo Clinic, Rochester, MN, USA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Electronic address: lehman.julia@mayo.edu. KEYWORDS: Graft-versus-host disease; dermatopathology; transplant PMID: 29288097 DOI: 10.1016/j.jaad.2017.12.050 PubMed Commons home PubMed Commons 0 comments How to join PubMed Commons
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies | Immunology and Biotherapies | Scoop.it
Arce Vargas et al. use a mouse model expressing human FcγRs to show that antibodies
with isotypes equivalent to ipilimumab increase the CD8+ to Treg ratio by depleting
intra-tumoral Tregs to promote tumor rejection. In melanoma patients, response to
ipilimumab is associated with a high affinity FcγR polymorphism.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Inside Amgen’s Human Genome Experiment | Amgen Science

Inside Amgen’s Human Genome Experiment | Amgen Science | Immunology and Biotherapies | Scoop.it
No company has made a larger bet on using human genetics to drive R&D than Amgen. Here’s an update on the company’s quest to focus its research on targets validated in humans.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Delivery of NF-κB shRNA using carbamate-mannose modified PEI for eliminating cancer stem cells

Delivery of NF-κB shRNA using carbamate-mannose modified PEI for eliminating cancer stem cells | Immunology and Biotherapies | Scoop.it
The presence of cancer stem cells (CSCs) is one of the main reasons that cause cancer
relapse and metastasis. In this study, NF-κB shRNA was delivered to target CSCs using
carbamate-mannose modified PEI (CMP) as a non-viral gene vector. The polymer was synthesized
by blocking primary amine groups of branched PEI (10kDa) through nucleophilic addition
between PEI and protected mannose-functionalized cyclic carbonate, followed by mannose
deprotection. CMP/control shRNA nanocomplexes showed lower cytotoxicity and higher
transfection efficiency in 4T1 murine breast cancer cells than unmodified PEI/control
shRNA nanocomplexes.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships - Blue Latitude Health

Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships - Blue Latitude Health | Immunology and Biotherapies | Scoop.it
The scientific rationale behind immunotherapies in oncology, and how partnerships, co-marketing and positioning will shape the market in pharma.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies | Immunology and Biotherapies | Scoop.it
Checkpoint blockade has formally demonstrated that reactivating anti-tumor immune
responses can regress tumors. However, this only occurs in a fraction of patients.
Incorporating these therapies in more powerful combinations is thus a logical next
step. Here, we review functional roles of immune checkpoints and molecular determinants
of checkpoint-blockade clinical activity. Limited-size T cell-infiltrated tumors,
differing substantially from “self,” generally respond to checkpoint blockade. Therefore,
we propose that reducing tumor burden and increasing tumor immunogenicity are key
factors to improve immunotherapy. Lastly, we outline criteria to select proper immunotherapy
combination partners and highlight the importance of activity biomarkers for timely
treatment optimization.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

IVIG indications: hypogammaglobulinemia & peripheral neuropathy

IVIG indications: hypogammaglobulinemia & peripheral neuropathy | Immunology and Biotherapies | Scoop.it
AAAAI's Ask the Expert talks about IVIG indications: hypogammaglobulinemia & peripheral neuropathy.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism ... - PubMed - NCBI

A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism ... - PubMed - NCBI | Immunology and Biotherapies | Scoop.it
Dermatol Ther (Heidelb). 2018 Apr 6. doi: 10.1007/s13555-018-0235-4. [Epub ahead of print] Review
more...
No comment yet.
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Antibody–Drug Conjugates for Cancer Treatment | Annual Review of Medicine

Antibody–Drug Conjugates for Cancer Treatment | Annual Review of Medicine | Immunology and Biotherapies | Scoop.it
The concept of exploiting the specific binding properties of monoclonal antibodies as a mechanism for selective delivery of cytotoxic agents to tumor cells is an attractive solution to the challenge of increasing the therapeutic index of cell-killing agents for treating cancer.

Via Krishan Maggon
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma

Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma | Immunology and Biotherapies | Scoop.it
This study demonstrates that IL13Rα2-targeted CAR-modified T cells have anti-tumor
activity in immunocompetent glioma models. While CAR T cells reversed the immunosuppressive
glioma microenvironment, their effector function was eventually eroded. These results
provide the rationale to explore combinatorial therapies or additional genetic modifications
to enhance the anti-glioma activity of CAR T cells.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Personalized ovarian cancer vaccine shows promise in pilot trial

Personalized ovarian cancer vaccine shows promise in pilot trial | Immunology and Biotherapies | Scoop.it
A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and the Abramson Cancer Center of the University of Pennsylvania
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Film: Tumour Immunology and Immunotherapy

Film: Tumour Immunology and Immunotherapy | Immunology and Biotherapies | Scoop.it
Watch this informative Nature video, which describes how the immune system interacts with a tumour and how immunotherapy treatments are designed to work.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

An Isolated TCR αβ Restricted by HLA-A*02:01/CT37 Peptide Redirecting CD8+ T Cells To Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines

An Isolated TCR αβ Restricted by HLA-A*02:01/CT37 Peptide Redirecting CD8+ T Cells To Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines | Immunology and Biotherapies | Scoop.it
Lung cancer is a leading cause of cancer-related death among both men and women in the United States, where non–small cell lung cancer accounts for ∼85% of lung cancer. Lung adenocarcinoma (ADC) is the major histologic subtype. The presence of actionable mutations prompts the use of therapies designed to specifically address the deleterious effects of those cancer-driving mutations; these therapies have already shown promise in cases carrying those actionable mutations (∼30%). Innovative therapeutic approaches are needed for the treatment of 70% of patients suffering from lung ADC. Adoptive transfer of CD8+ T cells specific against cancer/testis (CT) Ags, whose protein expression is restricted to the gonads (testis and ovary) and cancerous cells, is an excellent alternative. In this study, we report the isolation of HLA-A*02:01/CT37 peptide–specific α and β TCR chains from a CD8+ T cell clone obtained from a patient suffering from lung ADC. We also report the development of an innovative CD3ζ construct. With those TCR chains and the engineered (modified) CD3ζ chain, we produced a construct that when transduced into CD8+ T cells is capable of redirecting transduced CD8+ T cell cytotoxic activity and IFN-γ secretion against peptide-pulsed autologous cells and HLA-A*02:01 –positive and CT37-expressing lung ADC cell lines. Our findings will launch the development of innovative adoptive transfer immunotherapies for the treatment of lung ADC, targeting the most prevalent HLA molecules and CT37 peptides restricted by these molecules.
more...
No comment yet.